Haase-Statz S, Smalley R V
Synertron, Inc., Madison, Wisconsin, USA.
Oncology (Williston Park). 1999 Aug;13(8):1147-59; discussion 1159-60, 1163.
Recombinant interferon-alfa (Intron A, Roferon-A) has been under investigation as a therapeutic agent for non-Hodgkin's lymphoma (NHL) for 25 years. It has antitumor efficacy in a number of histologic subtypes but has not been accepted as a clinically useful agent by the majority of oncologists/hematologists. A total of 10 prospective, randomized trials of interferon-alfa have been conducted in patients with follicular lymphoma. A survival benefit associated with interferon-alfa has been demonstrated in three of these trials, which used an anthracycline-based combination chemotherapy induction regimen, primarily in patients with bulky symptomatic disease. In this article, we review these trials, as well as the use of interferon-alfa in other NHL subtypes. Based on these data, we support the recommendation that interferon-alfa be added to an anthracycline-based induction regimen in the treatment of patients with clinically or histologically aggressive follicular lymphoma. This agent also appears to be effective in patients with diffuse large B-cell lymphoma and in patients with cutaneous T-cell lymphoma. Preliminary clinical data support the need for prospective, randomized phase III trials evaluating the role of interferon-alfa in these disorders.
重组干扰素-α（安福隆、罗扰素）作为非霍奇金淋巴瘤（NHL）的治疗药物已被研究了25年。它对多种组织学亚型具有抗肿瘤疗效，但大多数肿瘤学家/血液学家尚未将其视为临床上有用的药物。共对滤泡性淋巴瘤患者进行了10项关于干扰素-α的前瞻性随机试验。其中三项试验证明了干扰素-α具有生存获益，这些试验使用了以蒽环类药物为基础的联合化疗诱导方案，主要针对有大块症状性疾病的患者。在本文中，我们回顾了这些试验以及干扰素-α在其他NHL亚型中的应用。基于这些数据，我们支持在治疗临床或组织学上侵袭性滤泡性淋巴瘤患者时，将干扰素-α添加到以蒽环类药物为基础的诱导方案中的建议。该药物在弥漫性大B细胞淋巴瘤患者和皮肤T细胞淋巴瘤患者中似乎也有效。初步临床数据支持有必要进行前瞻性随机III期试验，以评估干扰素-α在这些疾病中的作用。
